Jhanelle E. Gray

34.0k citations

215 papers · 5.3k indexed · 4 hit papers · h-index 39

Impact in

Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment

Papers in

Oncology 150
- Cancer Immunotherapy and Biomarkers 76
- Lung Cancer Research Studies 40
- Colorectal Cancer Treatments and Studies 29
Pulmonary and Respiratory Medicine 138
- Lung Cancer Treatments and Mutations 122
- Lung Cancer Diagnosis and Treatment 40

Co-authors: Matthew B. Schabath Scott Antonia Alberto Chiappori Eric B. Haura Robert J. Gillies Ilke Tunali Tawee Tanvetyanon Byoung Chul Cho
Journals: Journal of Clinical Oncology (51 papers)Journal of Thoracic Oncology (26 papers)Annals of Oncology (20 papers)Lung Cancer (9 papers)Clinical Cancer Research (6 papers)
Partner nations: United States South Korea United Kingdom

In The Last Decade

Jhanelle E. Gray

195 papers receiving 5.2k citations

Hit Papers

align trajectories log scale

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer 2023 · 130 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 Nature Communications
2022 Journal of Clinical Oncology
2019 Journal of Thoracic Oncology
2018 Annals of Oncology

Peers

Countries citing papers authored by Jhanelle E. Gray

Since Specialization

Citations

This map shows the geographic impact of Jhanelle E. Gray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jhanelle E. Gray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jhanelle E. Gray more than expected).

Fields of papers citing papers by Jhanelle E. Gray

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jhanelle E. Gray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jhanelle E. Gray. The network helps show where Jhanelle E. Gray may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jhanelle E. Gray, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jhanelle E. Gray Line = papers co-authored together Jhanelle E. Gray links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Real-World Clinical Characteristics, Treatment Patterns, and Clinical Outcomes in US Patients with Stage I–III Resected NSCLC Without Known EGFR Mutations: The RESECT Study Drugs - Real World Outcomes ·Jhanelle E. Gray, D07 Committee, Fransiskus Dewo Argo Utomo, Alice Wang, Ling Cai, G. Barrie Wetherill, C Courtine, Monami Akita, Nefeli Georgoulia	2025	0
2	LBA50 Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study Annals of Oncology ·Mariano Provencio, Mark M. Awad, Tina Cascone, H. H. Beeghly, Jie He, Shun Lü, Aurelia Alexandru, 大輔石出, Robin Cornelissen, Lía Raquel Oliveira, (unknown), J-L. Pujol, Helena Sopanen, Jhanelle E. Gray, C. Coronado Erdmann, Nancy Sekyi Whyte, Ogbuokebe S.K, Ratthapon Wonwandee, Fumihiro Tanaka	2024	9
3	1309P A genomic scar based signature (HRDsig) and biallelic BRCA alterations identify a homologous recombination deficiency (HRD) phenotype of non-small cell lung cancer (NSCLC) potentially actionable to the PARP inhibitor rucaparib: Post-hoc analysis of lung-MAP substudy S1900A Annals of Oncology ·Jonathan W. Riess, Jieling Miao, Paul Wheatley‐Price, Karen L. Reckamp, David Kozono, Karaya Morris, Martin J. Edelman, A.I. Guseva, Maria Magalhães Vasconcelos Guedes, Linda Corum, Ashok Gowda, Gordan Srkalović, Raymond U. Osarogiagbon, Megan Baumgart, SABREEN SAYED, 程森林, Hossein Borghaei, Jhanelle E. Gray, Roy S. Herbst, Karen Kelly	2024	1
4	A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer Advances in Therapy ·Christina S. Baik, Michael L. Cheng, Martin Dietrich, Jhanelle E. Gray, Nagla Abdel Karim	2024	1
5	Lung-MAP S1800D: A phase II/III study of N-803 (ALT-803) plus pembrolizumab versus standard of care in participants with stage IV or recurrent non-small cell lung cancer (NSCLC) previously treated with anti-PD-1 or anti-PD-L1 therapy. Journal of Clinical Oncology ·محسن دهقانپور فراشاه, Mary W. Redman, Hatim Husain, Karen L. Reckamp, Maysa M. N. Taha, Владимир Драгојловић, Ticiana Leal, Bryan A. Faller, Katherine Minichiello, Hossein Borghaei, Karen Kelly, Roy S. Herbst, Jhanelle E. Gray	2024	2
6	S1701: A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma. Journal of Clinical Oncology ·Anne S. Tsao, Philipp Böttcher, Marianna Koczywas, Marcelo Cavalcante, Jonathan W. Riess, Tawee Tanvetyanon, Zahra Zendehbad, Ying‐Qi Zhao, Mary W. Redman, Владимир Драгојловић, David R. Gandara, Karen Kelly, Jhanelle E. Gray	2024	3
7	SWOG S2302, PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (PR) versus standard of care (SOC) for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer. Journal of Clinical Oncology ·Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev, Wade T. Iams, Brian S. Henick, Jieling Miao, Michael LeBlanc, Daniel R. Carrizosa, Roy S. Herbst, Charles D. Blanke, Jhanelle E. Gray	2024	5
8	Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results. Journal of Clinical Oncology ·Andreas Saltos, Tawee Tanvetyanon, Ben Creelan, Michael Shafique, Scott Antonia, Eric B. Haura, Hong Zheng, Xiaoqing Yu, James J. Saller, Erica Strait, Ram Thapa, Theresa A. Boyle, Dung‐Tsa Chen, Amer A. Beg, Jhanelle E. Gray	2023	2
9	Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation Journal of Thoracic Disease ·Ahmet Bayraktar, Ram Thapa, 泰太郎小寺, Michael Shafique, Andreas Saltos, Ben Creelan, Tawee Tanvetyanon, Alberto Chiappori, George R. Simon, Eric B. Haura, Jhanelle E. Gray, Dung‐Tsa Chen, James T. Bayorgeon, Bruna Pellini	2023	4
10	Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer Nature Communications ·Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng‐Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Wilda Olivares, Aleksandra Markovets, J. Carl Barrett, Ryan J. Hartmaier, Suresh S. Ramalingam Hit paper breakdown →	2023	130
11	Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy Cancers ·Dung‐Tsa Chen, Andreas Saltos, Trevor Rose, Zachary Thompson, Ram Thapa, Alberto Chiappori, Jhanelle E. Gray	2023	2
12	Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer Clinical Cancer Research ·Alberto Chiappori, Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, Ram Thapa, MUDr.Pavel Frühauf, Zhihua Chen, Xia Zixu, Amer A. Beg, Theresa A. Boyle, Isabelle Araújo Neri, Ara Bella, Erick J. Morris, Mehreteab Aregay, Felipe K. Hurtado, Luigi Manenti, Scott Antonia	2022	50
13	Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer JNCI Cancer Spectrum ·Ilke Tunali, Yan Tan, Jhanelle E. Gray, Evangelia Katsoulakis, Steven A. Eschrich, James J. Saller, Hugo J.W.L. Aerts, Theresa A. Boyle, Jin Qi, Albert Güveniş, Robert J. Gillies, Matthew B. Schabath	2021	31
14	Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology Practice JCO Precision Oncology ·J. Kevin Hicks, Rachel Howard, Yuefei Wang, Jacob J. Adashek, Karen K. Fields, Jhanelle E. Gray, Bryan McIver, 大野直美, Dylan De Choch, Randa Perkins, Edmondo Robinson, Ankita Tandon, Jamie K. Teer, Joseph Markowitz, Dana E. Rollison	2021	31
15	Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer PLoS ONE ·Dung‐Tsa Chen, Wenyaw Chan, Zachary Thompson, Ram Thapa, Amer A. Beg, Andreas Saltos, Alberto Chiappori, Jhanelle E. Gray, Eric B. Haura, Trevor Rose, Ben Creelan	2021	4
16	RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry Lung Cancer ·April Deveaux, Tyler A. Allen, Muthana Al Abo, Xiaodi Qin, Dadong Zhang, Zhao Xu, Lin Gu, Jhanelle E. Gray, Chad V. Pecot, Holly K. Dressman, Shannon J. McCall, Rick A. Kittles, Terry Hyslop, Kouros Owzar, Jeffrey Crawford, Steven R. Patierno, Jeffrey Clarke, Jennifer A. Freedman	2021	5
17	Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer Clinical Cancer Research ·Jhanelle E. Gray, Andreas Saltos, Tawee Tanvetyanon, Eric B. Haura, Ben Creelan, Scott Antonia, Michael Shafique, Hong Zheng, Wenjie Dai, James J. Saller, Zhihua Chen, Nishan Tchekmedyian, Taraneh Moghani, Ram Thapa, Theresa A. Boyle, Dung‐Tsa Chen, Amer A. Beg	2019	104
18	Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer European Journal of Cancer ·Natasha B. Leighl, Nina Karaseva, Kazuhiko Nakagawa, Byoung Chul Cho, Jhanelle E. Gray, Somia BENCHIKH, Andrew Walding, Anna Rydén, Silvia Novello	2019	46
19	<p>A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer</p> Cancer Management and Research ·Matthew B. Schabath, Tapashi Dalvi, Hongyue Dai, Yang Li, Anita Midha, Norah J. Shire, 丛淑珍, Jill Walker, Danielle Greenawalt, David Lawrence, James R. Rigas, Robert S. Brody, Danielle Potter, Robert Costiera, Esin Taboglu, Jhanelle E. Gray	2019	1
20	PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer Molecular Cancer Therapeutics ·栗国平, Nicholas T. Woods, Gabriëla Wright, Lily L. Remsing Rix, Fumi Kinose, Jodi L. Kroeger, Elizabeth Remily-Wood, W. Douglas Cress, John M. Koomen, Stephen G. Brantley, Jhanelle E. Gray, Eric B. Haura, Uwe Rix, Álvaro N.A. Monteiro	2016	21

About Jhanelle E. Gray

Jhanelle E. Gray is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Radiology, Nuclear Medicine and Imaging and Immunology, having authored 215 papers that have together received 5.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (122 papers), Cancer Immunotherapy and Biomarkers (76 papers), Lung Cancer Diagnosis and Treatment (40 papers), Lung Cancer Research Studies (40 papers), Cancer Genomics and Diagnostics (38 papers), Colorectal Cancer Treatments and Studies (29 papers), Radiomics and Machine Learning in Medical Imaging (17 papers) and PI3K/AKT/mTOR signaling in cancer (12 papers). The work is most often cited by research in Oncology (3.0k citations), Pulmonary and Respiratory Medicine (2.8k citations), Cancer Research (845 citations), Radiology, Nuclear Medicine and Imaging (778 citations) and Immunology (514 citations). Jhanelle E. Gray has collaborated with scholars based in United States, South Korea and United Kingdom. Frequent co-authors include Matthew B. Schabath, Scott Antonia, Alberto Chiappori, Eric B. Haura, Robert J. Gillies, Ilke Tunali, Tawee Tanvetyanon, Byoung Chul Cho, Ben Creelan and Wei Mu. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology, Lung Cancer and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact